Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Irinotecan has demonstrated activity in malignant gliomas in multiple phase II studies. The
activity is limited, with an approximately 15 % response rate and a progression-free survival
of 3-5 months. Given the synergy between irinotecan and bevacizumab in colorectal cancer, and
the high-level expression of vascular endothelial growth factor on malignant gliomas, one
would expect synergy between bevacizumab and irinotecan against gliomas. In addition, 40-50 %
of GBM have EGFR amplification/mutation making the EGFR an additional target. By combing
cetuximab, with irinotecan and bevacizumab, one would expect further response, than
irinotecan and bevacizumab alone. In addition, recurrent gliomas have an extremely poor
prognosis, so innovative therapies are needed.
Phase:
Phase 2
Details
Lead Sponsor:
Rigshospitalet, Denmark
Collaborators:
Aalborg Universitetshospital Aalborg University Hospital Odense University Hospital